PIK3CD and cancer: If the tolerability can be improved, perhaps dual PI3K/mTOR inhibitors could be beneficial for cancer therapy because studies have shown PI3K to be involved in chemotherapy resistance (Cleary and Shapiro, 2010; Garber, 2014).